Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Meridian Bioscience Inc.

Begin initial shipments of the Revogene SARS-CoV-2 assay to select customers

Not delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
7 Jan 2021
Due
14 Jan 2021
Checked
24 Oct 2026
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“its own contribution to the fight begins in the coming week with initial shipments of the Revogene SARS-CoV-2 assay to select customers expected.”

What we found

Evidence strength A What the grades mean

The company did not ship the assay as planned; it subsequently withdrew its EUA application in February 2021, halting shipments until receiving FDA clearance in November 2021.

  • A
    Meridian Bioscience Inc. 10-Q filed 2021-05-07 Regulatory filing · published 7 May 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint 75b7a81c35fb
    “We will not resume shipments of the Revogene COVID-19 assay until FDA EUA clearance.” ✓ confirmed on the page
  • A
    Meridian Bioscience Inc. 10-Q filed 2021-08-06 Regulatory filing · published 6 Aug 2021 · retrieved 24 Oct 2026 · kept permanently by the SEC · fingerprint 7a93cde47804
    “our pending SARS-CoV-2 assay emergency use authorization (“EUA”) application, which we voluntarily withdrew from the FDA on February 23, 2021” ✓ confirmed on the page

Checked 24 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Production start
Indicative materiality
High rules
Action
Begin
Deliverable
Revogene SARS-CoV-2 assay shipments
Language
Expected (“expects”, “plans”)
In the company’s control
High
Specificity
High
Depends on
Customer

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
  4. Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Meridian Bioscience Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C794172-021271 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.